Symphogen A/S – Product Pipeline Review – H2 2011

Table of Contents 2
List of Tables 4
List of Figures 5
Symphogen A/S Snapshot 6
Symphogen A/S Overview 6
Key Information 6
Key Facts 6
Symphogen A/S – Research and Development Overview 7
Key Therapeutic Areas 7
Symphogen A/S – Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products – Monotherapy 10
Symphogen A/S – Pipeline Products Glance 11
Symphogen A/S Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Symphogen A/S–Early Stage Pipeline Products 12
Pre-Clinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
Symphogen A/S – Drug Profiles 14
Sym001 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Sym002 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Sym003 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Sym005 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Sym006 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Sym007 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Sym008 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Tie-1 Tyrosine Kinase Inhibitor 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Symphogen A/S – Pipeline Analysis 22
Symphogen A/S – Pipeline Products by Therapeutic Class 22
Symphogen A/S - Pipeline Products By Target 24
Symphogen A/S – Pipeline Products by Route of Administration 25
Symphogen A/S – Pipeline Products by Molecule Type 26
Symphogen A/S – Recent Pipeline Updates 27
Symphogen A/S - Dormant Projects 29
Symphogen A/S – Company Statement 30
Symphogen A/S – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Aug 23, 2011: Symphogen Initiates Phase II Trial Of Sym004 EGFR Antibody Mixture In Patients With Squamous Cell Carcinoma Of Head And Neck Cancer 33
Nov 20, 2008: Biovitrum And Symphogen Reports Positive Clinical Results Of Sym001 In Novel Rh-immunization Prevention Project 33
Jul 16, 2008: Symphogen And Biovitrum Initiate Phase II Clinical Trial Of Sym001 In Idiopathic Thrombocytopenic Purpura Patients 34
Apr 15, 2008: Biovitrum And Symphogen Initiate A Second Clinical Study With Sym001 For Treatment Of Hemolytic Diseases 35
Mar 12, 2007: Symphogen And Biovitrum Initiate Phase I Clinical Trial With Sym001 To Enter Clinical Evaluation 35
Jan 11, 2010: Symphogen Publishes Pre-Clinical Data Of Sym004 In The On-Line Edition Of Cancer Research 36
Jun 10, 2011: Symphogen Presents Preliminary Results From Phase II Clinical Trial With Rozrolimupab At Annual European Hematology Association 36
Mar 07, 2011: Symphogen Presents Sym004 Preclinical Data At Major Oncology Meetings 37
Mar 07, 2011: Symphogen Receives US Patent On Lead Cancer Compound Sym004 38
Oct 06, 2010: Symphogen And Swedish Orphan Biovitrum Receive US Orphan Drug Designation For Rozrolimupab In Immune Thrombocytopenia 38
Jun 06, 2011: Symphogen Presents Results From First Clinical Trial With Sym004 At ASCO 39
Feb 06, 2008: Biovitrum And Symphogen have Successfully Completed Phase I Clinical Trial With Sym001 40
Dec 04, 2007: Symphogen Presents Positive Preclinical Data On Sym003 Program For RSV Infection 40
Dec 04, 2006: Symphogen And Meiji Seika Kaisha Ltd. Achieve Milestone In Discovery Collaboration For Recombinant Polyclonal Antibody, Sym006 41
Dec 01, 2008: Symphogen To Present Positive Preclinical Data On Sym004 Program For EGF-Receptor Positive Cancers 42
Jun 01, 2011: Symphogen To Present Data From First Clinical Trial With Sym004 At ASCO 42
Apr 01, 2010: Symphogen Initiates Phase I/II Trial Of Sym004 In Patients With Advanced Solid Tumors In US 42
Feb 01, 2006: Biovitrum And Symphogen Enter Co-Development And Commercialization Agreement For Sym001 For The Treatment Of Certain Blood Disorders 43
Financial Deals Landscape 45
Symphogen A/S, Deals Summary 45
Symphogen A/S, Pharmaceuticals & Healthcare, Deal Details 47
Asset Transactions 47
Symphogen Acquires Technology From Receptor BioLogix 47
Venture Financing 48
SYMPHOGEN Raises $132 Million In Venture Financing 48
Symphogen Secures $44 Million In Venture Financing 50
Symphogen Secures $6.5 Million In Venture Financing 52
Symphogen Secures $25 Million In Series D Financing Round 53
Symphogen Secures $25 Million In Series C Financing 55
Symphogen Secures $2.5 Million In Venture Financing 57
Partnerships 58
Origen Therapeutics Enters Into Collaboration Agreement With Symphogen 58
Symphogen Enters Co-Development Agreement With Genentech 59
Meiji Seika Enters Into An Agreement With Symphogen 60
Biovitrum Enters Into Co-Development Agreement With Symphogen 61
Licensing Agreements 63
RheoGene Enters Into Licensing Agreement With Symphogen For AttSite 63
Symphogen Enters Into Licensing Agreement With MedImmune 64
Crucell And DSM Enter Into Licensing Agreement With Symphogen 65
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 67
Contact Us 67
Disclaimer 67

List of Tables

Symphogen A/S – Pipeline by Therapy Area and Indication, H2 2011 8
Symphogen A/S – Pipeline by Stage of Development, H2 2011 9
Symphogen A/S – Monotherapy Products in Pipeline, H2 2011 10
Symphogen A/S - Phase II, H2 2011 11
Symphogen A/S - Pipeline By Therapeutic Class, H2 2011 23
Symphogen A/S - Pipeline By Target, H2 2011 24
Symphogen A/S – Pipeline By Route of Administration, H2 2011 25
Symphogen A/S – Pipeline By Molecule Type, H2 2011 26
Symphogen A/S – Recent Pipeline Updates, H2 2011 27
Symphogen A/S - Dormant Developmental Projects, 2010 29
Symphogen A/S, Subsidiaries 32
Symphogen A/S, Deals Summary 45
Symphogen Acquires Technology From Receptor BioLogix 47
SYMPHOGEN Raises $132 Million In Venture Financing 48
Symphogen Secures $44 Million In Venture Financing 50
Symphogen Secures $6.5 Million In Venture Financing 52
Symphogen Secures $25 Million In Series D Financing Round 53
Symphogen Secures $25 Million In Series C Financing 55
Symphogen Secures $2.5 Million In Venture Financing 57
Origen Therapeutics Enters Into Collaboration Agreement With Symphogen 58
Symphogen Enters Co-Development Agreement With Genentech 59
Meiji Seika Enters Into An Agreement With Symphogen 60
Biovitrum Enters Into Co-Development Agreement With Symphogen 61
RheoGene Enters Into Licensing Agreement With Symphogen For AttSite 63
Symphogen Enters Into Licensing Agreement With MedImmune 64
Crucell And DSM Enter Into Licensing Agreement With Symphogen 65

List of Figures

Symphogen A/S – Pipeline by Therapy Area and Indication, H2 2011 8
Symphogen A/S – Pipeline by Stage of Development, H2 2011 9
Symphogen A/S – Monotherapy Products in Pipeline, H2 2011 10
Symphogen A/S – Pipeline By Therapeutic Class, H2 2011 22
Symphogen A/S - Pipeline By Target, H2 2011 24
Symphogen A/S – Pipeline By Molecule Type, H2 2011 26